Furthermore, despite the attenuated risk, the major confounders HbA1C and DM duration did not change the relationship between insulin treatment and adverse outcomes, with an adjusted HR of 2.16 (95% CI, 1.08–4.59; P = 0.030) (Table 6). The gene discussed is INS; the disease is diabetes mellitus.